Abstract
To the Editor: The report by Donahue et al. (Aug. 6 issue)1 documented the dramatic decrease in the risk of transmitting hepatitis C virus (HCV) through blood transfusion as a result of sequential improvements in blood-donor testing over the past five years. The authors' data included measurements of the risk of HCV from blood screened by tests for surrogate markers of non-A, non-B hepatitis (antibody to the hepatitis B core antigen [anti-HBc] and elevated levels of alanine aminotransferase) and by a first-generation enzyme immunoassay (EIA) for antibodies to HCV (anti-HCV). The authors stated that the recent implementation of a second-generation…
Original language | English (US) |
---|---|
Pages (from-to) | 1601-1602 |
Number of pages | 2 |
Journal | New England Journal of Medicine |
Volume | 327 |
Issue number | 22 |
DOIs | |
State | Published - Nov 26 1992 |
ASJC Scopus subject areas
- Medicine(all)